1 The EIC Accelerator Project

The EIC Accelerator program is a pivotal initiative under the European Innovation Council (EIC) designed to support innovative small and medium-sized enterprises (SMEs) and startups in Europe, particularly in the DeepTech sector. The program aims to bridge the funding gap for companies that are developing cutting-edge technologies with high growth potential but require financial assistance to scale their operations and bring their innovations to market.

Funding Structure

The EIC Accelerator offers a dual funding mechanism comprising grants and equity investments.

Purpose in the Ecosystem

The EIC Accelerator plays a crucial role in the European DeepTech and startup ecosystem. Its primary purpose is to foster innovation by providing financial backing to companies that are often too risky for traditional investors. By backing high-risk, high-reward projects, the EIC Accelerator helps to ensure that groundbreaking technologies can be developed and commercialized, thus driving economic growth and job creation in Europe.

Additionally, the program strengthens the relationship between startups and private investors. EIC Accelerator funding acts as a validation signal to private investors, enhancing their confidence in the project's viability. This, in turn, facilitates further investment from the private sector, enabling companies to secure the necessary resources for scaling up their operations.

Case Study: Freiburger Medizintechnik GmbH and the AmbiJet Project

Freiburger Medizintechnik GmbH, a German company focused on advanced medical technologies, is a notable winner of the EIC Accelerator. The company submitted its Step 2 proposal for the AmbiJet project on March 23, 2022, successfully advancing to the Step 3 interview stage, where it secured funding.

AmbiJet Project Overview

The AmbiJet project is groundbreaking, being marketed as the world's first highly effective plasma-based solution aimed at addressing peri-implantitis, a condition afflicting approximately 16 million patients in Europe who have dental implants. Peri-implantitis is characterized by inflammation of the tissues surrounding a dental implant, often leading to implant failure if left untreated. The AmbiJet solution is designed to provide a minimally invasive treatment option that targets the underlying causes of this condition.

Technology Basics and Background

The core technology behind AmbiJet revolves around the application of cold plasma, a state of matter distinct from solids, liquids, and gases, where a portion of the gas is ionized. This innovative approach harnesses the antimicrobial properties of plasma to eliminate harmful bacteria and promote healing in the peri-implant region.

Cold plasma has been shown to be effective in various medical applications due to its ability to generate reactive species that can disrupt bacterial cell walls while being gentle enough to not damage surrounding tissues. The technology is particularly appealing in dental applications where precision and patient comfort are paramount.

Freiburger Medizintechnik GmbH has conducted extensive research and development to optimize the AmbiJet system, ensuring that it is both effective and safe for clinical use. The company’s efforts not only aim to improve patient outcomes but also to reduce the economic burden associated with dental implant failures, which can be significant.

In summary, the EIC Accelerator program serves as a vital catalyst for innovation, particularly in the DeepTech sector, by providing essential funding and support to startups and SMEs. The success of Freiburger Medizintechnik GmbH with the AmbiJet project exemplifies the program's impact on advancing medical technologies that address pressing health challenges in Europe.

2 The Funding Rounds

Financing Raised and Funding Rounds

Freiburger Medizintechnik GmbH, based in Germany, has secured several rounds of financing since its founding and particularly after being awarded EIC Accelerator funding in March 2022.

Summary of Key Funding Events:

Date	Round/Source	Amount
Oct 2019	EXIST (German Program)	€180k
Jul 2021	Angel	€300k
Jan 2022	EIT Health	€2.0k
Mar 2022	European Innovation Council (EIC Accelerator)	€1.4m

• The company received early support from the German Federal Ministry for Economic Affairs and Energy via the EXIST program, a common pre-seed grant for innovative startups in Germany.
• An angel investment round followed in July 2021.
• In January 2022, Freiburger Medizintechnik received a small grant from EIT Health, a prominent EU health innovation network.
• Most significantly, they secured approximately €1.4 million from the highly selective European Innovation Council (EIC) Accelerator program following their successful Step 3 interview after submitting their proposal on March 23, 2022.

Additionally, company materials confirm that they have been beneficiaries of multiple public funding sources over time—including national German programs and EU initiatives—underlining continued institutional investor confidence.

Investor Information

The specific names of private investors or venture capital firms involved with Freiburger Medizintechnik are not publicly disclosed in available sources. However:

• Angel investors participated in the July 2021 round.
• Institutional support comes via governmental bodies such as:
• German Federal Ministry for Economic Affairs and Energy
• European Social Funds
• The EXIST Program
• European Union’s EIC Accelerator scheme

Company Valuations

No publicly reported valuations are available for Freiburger Medizintechnik GmbH following these funding rounds.

Exit Events (IPO/Buyouts/Acquisitions)

There is no evidence to suggest that Freiburger Medizintechnik has undergone an exit event such as an IPO or acquisition as of April 24th, 2025.

---

Sources:

• About us – Freiburger Medizintechnik
• Freiburger Medizintechnik company information – Startup Luxembourg
• Freiburger Medizintechnik homepage

3 The Press Releases

Freiburger Medizintechnik GmbH: EIC Accelerator Funding and Developments

Freiburger Medizintechnik GmbH, a German company based in Freiburg, received EIC Accelerator funding in March 2022. Since then, the company has been actively advancing its innovative dental technology, particularly focusing on the prevention and treatment of peri-implantitis, a common issue affecting dental implants.

Technology Advancements

Freiburger Medizintechnik's key innovation is the AmbiJet system, which utilizes plasma jet technology to effectively disinfect dental implants without chemicals or liquids. This breakthrough in plasma medicine combines expertise in microsystems engineering and plasma physics to provide a fast, painless, and side-effect-free treatment for peri-implantitis.

Partnerships and Recognition

The company has been recognized as one of the runner-ups in EIT Health's Catapult program for 2022-2023, indicating its potential in the health technology sector. Additionally, Freiburger Medizintechnik has participated in major dental and medical technology events, such as MedTec Live and the International Dental Show (IDS).

Team and Research Background

Freiburger Medizintechnik is a spin-off from the University of Freiburg's Department of Microsystems Engineering (IMTEK), one of the world's largest research centers for microsystems engineering. The company's international team includes engineers, physicists, biologists, and dentists, reflecting its interdisciplinary approach to solving dental health challenges.

Press Releases and Updates

While specific press releases from the company's website are not detailed, updates include ongoing research and development in plasma technology for dentistry. Their scientific publications highlight the potential of guided plasma applications as an alternative to antibiotic therapy for dental infections.

Future Outlook

Given the growing concern over peri-implantitis and the increasing number of dental implants worldwide, Freiburger Medizintechnik is well-positioned to address this emerging health issue with its innovative AmbiJet technology.

---

Sources: - Freiburger Medizintechnik | The implant care company

• News | Freiburger Medizintechnik
• Freiburger Medizintechnik on Badische Zeitung
• Freiburger Medizintechnik GmbH — Supplier from Germany
• Sitemap | Freiburger Medizintechnik

4 The Technology Advancements

Freiburger Medizintechnik GmbH: Post-EIC Accelerator Developments Since securing EIC Accelerator funding in March 2022, Freiburger Medizintechnik (FrMED) has advanced its AmbiJet plasma technology platform, emphasizing clinical validation and market readiness. While explicit post-2022 updates on patents or new trials are not publicly documented, the company’s trajectory aligns with its stated mission of delivering "a device for the best possible implant care" through technological and clinical excellence.

Core Capabilities

FrMED specializes in cold atmospheric plasma (CAP) systems, particularly its flagship AmbiJet device, designed for antimicrobial applications and tissue regeneration in dental and implant care. The technology leverages reactive oxygen and nitrogen species to target biofilms without harming surrounding tissues. Key capabilities include:

• Antibacterial efficacy: Proven against biofilm-associated infections, critical for peri-implantitis treatment.
• Cell regeneration: Demonstrated acceleration of wound healing through plasma-induced cellular responses.

Post-Funding Advancements

While no new patents or peer-reviewed studies post-2022 are explicitly cited, FrMED has likely prioritized:

• Clinical validation: Building on prior studies referenced in their whitepaper showing CAP’s effectiveness against pathogens like Staphylococcus aureus and Candida albicans. The company emphasizes collaboration with institutions such as Universidad Rey Juan Carlos for clinical trials.
• Technological refinement: Continued optimization of AmbiJet’s portability and user interface, aligning with their focus on "technological prowess" highlighted in corporate materials.

Market Engagement & Demonstrations

FrMED actively promotes AmbiJet as a CE-marked medical device but lacks publicly disclosed pilot programs or customer case studies since 2022. Their 2023 whitepaper positions the system as ready for clinical adoption, suggesting ongoing efforts to penetrate dental clinics and hospitals specializing in implantology.

---

Sources

• AMBIJET - Freiburger Medizintechnik Whitepaper
• About FrMED

5 The Partnerships and Customers

Freiburger Medizintechnik GmbH: Partnerships and Growth Opportunities

Freiburger Medizintechnik GmbH, located in Germany, is known for its expertise in implant care and has been recognized as an EIC Accelerator winner in March 2022. However, specific details about its partnerships, new partners, or new customers are not readily available in the search results. The company is engaged in scientific research and publications, particularly in the fields of plasma and dentistry.

Current Status and Partnerships

Freiburger Medizintechnik GmbH does not have publicly disclosed partnerships or specific customer relations as of the latest available information. However, its involvement in scientific publications suggests a strong focus on research and collaboration within the medical technology sector.

New Relationships and Market Positioning

While there is no specific information about new partners or customers for Freiburger Medizintechnik GmbH, the EIC Accelerator funding received in March 2022 likely enhances its market positioning by providing financial support for innovation and growth. This funding can facilitate the expansion of its research capabilities and technology advancements.

Nature of New Relationships and Purpose

The absence of detailed information on new partnerships or customers means that the specific nature and purpose of any emerging relationships are not clear. However, the general goal of such collaborations in the medical technology sector often involves enhancing product development, expanding market reach, and improving technological capabilities.

Technology Advancements and Scaling

For Freiburger Medizintechnik GmbH, any potential new relationships or partnerships would likely be aimed at leveraging external expertise or resources to advance its technological offerings and scale operations. This could involve collaborations with research institutions, technology providers, or industry partners to enhance its implant care solutions.

Sources

• Freiburger Medizintechnik
• Scientific Publications - Freiburger Medizintechnik
• Medical Technology Clusters in Germany

6 The Hiring and Company Growth

Freiburger Medizintechnik GmbH Overview

Freiburger Medizintechnik GmbH, a German company specializing in medtech, particularly in implant care, gained significant recognition after winning the EIC Accelerator funding in March 2022. This funding marked a crucial milestone for the company, which combines expertise in plasma physics, microsystems engineering, life sciences, and dentistry.

Current Team and Hiring

While specific details about the current headcount or team size are not publicly available, the company's team includes diverse professionals such as plasma physicists, microsystem engineers, biologists, dentists, and experts in medical product documentation. The founding team includes Dr.-Ing. Loïc A. Ledernez, Dr.-Ing. Michael E. Bergmann, and Prof. Dr. med. dent. Markus J. Altenburger. There is no recent information available on whether they are currently hiring, but their focus on innovation suggests a potential for growth and new positions.

Growth and Scaling

The EIC Accelerator funding has likely contributed to the company's growth by supporting the development of innovative technologies like their AmbiJet device. This device showcases plasma technology's antibacterial and cell regeneration capabilities, positioning Freiburger Medizintechnik at the forefront of medtech innovation. The company's awards and recognition, such as being named MedTech Startup of the Year, indicate its upward trajectory in scaling and advancing in the medical technology sector.

Key Positions and Impact

Recent hiring information is not detailed, but the inclusion of diverse expertise suggests a focus on building a strong foundation in research and development. New team members would likely enhance the company's ability to develop and commercialize cutting-edge medical devices, which is crucial for scaling and future success.

Management and Founding Team Changes

There are no reported changes in the management or founding team since the EIC Accelerator funding. The current leadership remains consistent with the co-founders continuing to drive the company's vision and technological advancements.

Future Prospects

The addition of new team members and the continued development of innovative technologies like AmbiJet will be pivotal in Freiburger Medizintechnik's future growth. These advancements will help the company expand its market presence and contribute to the broader medtech sector in Germany, which is known for its innovation and SME-driven growth.

---

Sources:

• Freiburger Medizintechnik
• About Freiburger Medizintechnik

7 The Media Features and Publications

Freiburger Medizintechnik GmbH Overview

Freiburger Medizintechnik GmbH, a German company, has been making significant strides in the medical technology sector, particularly in dentistry. It received the EIC Accelerator funding on March 23, 2022, which marked a crucial milestone for its innovative projects.

Media Features

The company has been featured in various media outlets, primarily for its pioneering work in plasma technology for dental treatments. Their focus on peri-implantitis treatment has garnered attention due to the development of the AmbiJet system, which uses plasma jets to combat bacterial biofilms without antibioticsnews.vm.uni-freiburg.de.

Publications

Freiburger Medizintechnik GmbH has been named in several publications related to its research and innovations. One notable publication is on guided plasma application in dentistry, highlighting its potential as an alternative to antibioticsfrmed.de. Another significant publication analyzes future trends in the dental market, focusing on peri-implantitis, periodontitis, and endodonticsfrmed.de.

Content from Publications

Publications about Freiburger Medizintechnik often discuss its contributions to plasma medicine, particularly in treating peri-implantitis. The company's AmbiJet system is praised for its effectiveness in disintegrating biofilm and inactivating bacteria without the use of pharmaceutical substancescordis.europa.eu.

Podcasts and Interviews

There is no specific information available about podcasts or interviews featuring the team of Freiburger Medizintechnik GmbH. However, the company's work is often mentioned in contexts related to medical technology and dental innovations.

Conference and Fair Visits, Presentations

While there is no direct information on Freiburger Medizintechnik GmbH's participation in specific conferences or fairs, its involvement in the scientific community is evident through its research collaborations and publications. The company's focus on innovative dental treatments suggests potential participation in medical and dental conferences.

Involvement in Events

Freiburger Medizintechnik GmbH is an active participant in the scientific community, particularly in the field of dental medicine. Although specific event participations are not detailed, the company's research and development activities indicate significant engagement with academic and medical events.

Sources

• Scientific Publications - Freiburger Medizintechnik
• News | Freiburger Medizintechnik
• AmbiJet: the world's first and only highly effective plasma ...
• Start-up Freiburger Medizintechnik GmbH sichert Seed ...